Table 3.
Summary of each individual meta-analysis on associations of the use of statin and recurrence-free survival, progression-free survival and disease-free survival in various cancers.
| Type/Author, Year | Study Design | No of Study | No of Total Participants | Random Effects (Reported) (ES, 95%CI) |
Random Effects (Re-Analyzed) (ES, 95%CI) |
Fixed Effects (Re-Analyzed) (ES, 95%CI) |
Largest Effect § | Egger | I2 (P) † |
P (Random) |
P (Fixed) |
95% PI (Random) |
Small Study Effect | Same Direction | Evidence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurrence-free survival | |||||||||||||||
| Bladder cancer | |||||||||||||||
| Luo 2015 | Obs | 3 | 3571 | 1.05 (0.94–1.18) |
1.06 (0.94–1.19) |
1.06 (0.94–1.19) |
1.04 (0.96–1.24) |
0.844 | 0.0 (0.950) | 0.375 | 0.375 | 0.47–2.36 | No | Yes | Non-significant |
| Breast cancer | |||||||||||||||
| Manthravadi 2016 | Cohort | 10 | 32,373 | 0.64 (0.53–0.79) |
0.64 (0.52–0.79) |
0.69 (0.60–0.79) |
0.80 (0.64–1.00) |
0.093 | 44.0 (0.070) | <0.001 | <0.001 | 0.38–1.09 | Yes | Yes | Suggestive |
| Colorectal cancer | |||||||||||||||
| Cai 2015 | Obs | 2 | 1233 | 0.98 (0.36–2.70) |
0.98 (0.36–2.70) |
1.12 (0.58–2.15) |
1.28 (0.64–2.54) |
– | 26.1 (0.345) | 0.975 | 0.730 | NA | - | Yes | Non-significant |
| Kidney cancer | |||||||||||||||
| Nayan 2017 | Overall | 4 | 2197 | 0.97 (0.89–1.06) |
0.97 (0.89–1.06) |
1.00 (0.99–1.01) |
1.09 (0.65–1.81) |
0.364 | 55.2 (0.082) | 0.524 | 0.899 | 0.70–1.36 | No | Yes | Non-significant |
| Luo 2015 | Obs | 3 | 5080 | 0.91 (0.54–1.55) |
0.91 (0.54–1.55) |
1.00 (0.81–1.23) |
1.22 (0.95–1.57) |
0.783 | 72.0 (0.030) | 0.736 | 0.991 | 0.47–2.36 | No | Yes | Non-significant |
| Prostate cancer | |||||||||||||||
| Park 2013 | Cohort | 13 | 21,185 | 0.90 (0.74–1.08) |
0.90 (0.74–1.08) |
0.92 (0.84–1.00) |
0.99 (0.83–1.18) |
0.649 | 69.6 (<0.001) | 0.252 | 0.057 | 0.48–1.67 | No | Yes | Non-significant |
| Progression-free survival | |||||||||||||||
| Bladder cancer | |||||||||||||||
| Luo 2015 | Obs | 2 | 2069 | 0.87 (0.65–1.15) |
0.87 (0.65–1.15) |
0.87 (0.65–1.15) |
0.77 (0.52–1.13) |
0.461 | 0.0 (0.370) | 0.320 | 0.320 | NA | No | Yes | Non-significant |
| Endocrine gynecological cancer | |||||||||||||||
| Xie 2017 | Obs | 3 | 421 | - | 0.69 (0.46–1.02) |
0.68 (0.49–0.93) |
0.65 (0.39–1.07) |
0.439 | 33.6 (0.222) | 0.066 | 0.018 | 0.02–27.87 | No | Yes | Non-significant |
| Kidney cancer | |||||||||||||||
| Nayan 2017 | Overall | 2 | 4965 | 0.92 (0.51–1.65) |
0.92 (0.51–1.65) |
1.00 (0.82–1.23) |
0.67 (0.47–0.96) |
– | 86.2 (0.007) | 0.772 | 0.996 | NA | - | No | Non-significant |
| Prostate cancer | |||||||||||||||
| Luo 2015 | Obs | 5 | 6032 | 0.84 (0.62–1.14) |
0.84 (0.62–1.14) |
0.87 (0.71–1.05) |
1.10 (0.78–1.56) |
0.607 | 52 (0.080) | 0.260 | 0.148 | 0.34–2.10 | No | Yes | Non-significant |
| Disease-free survival | |||||||||||||||
| Colorectal cancer | |||||||||||||||
| Cai 2015 | Obs | 2 | 1233 | 1.13 (0.78–1.62) |
1.13 (0.78–1.62) |
1.13 (0.78–1.62) |
1.07 (0.68–1.67) |
- | 0.0 (0.691) | 0.514 | 0.514 | NA | - | Yes | Non-significant |
ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study; § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I2 metric of inconsistency (95% confidence interval of I2) and P-value of the Cochran Q test for evaluation of heterogeneity.